Pfizer's stock has started to turn higher, but it is still down massively; is now the time to jump aboard?

The agreement allows Pfizer to utilize Novavax’s Matrix-M adjuvant in up to two disease areas with its products. Under the terms of the deal, Novavax will receive an upfront payment of $30 million and ...

Pfizer (NYSE:PFE) has entered a non exclusive licensing agreement with Novavax for access to its Matrix-M adjuvant technology. The company is also participating in the White House TrumpRx initiative, ...

Pfizer is investing in oncology and GLP-1 drugs, among other things, to keep its growth prospects bright. Western Union is ...

Five months after ending development of its own obesity treatment, Pfizer is accelerating its push into the rapidly growing field with a nearly $5 billion acquisition. Minnesota CEOs urge ...

Pfizer Inc. (PFE) shares are trading higher on Tuesday, as the stock benefits from a price target increase at Cantor ...

Pfizer is one of the world's largest and oldest drug companies. Thanks to its Covid vaccine, shares rose dramatically during the pandemic. Now that the stock has sharply corrected, long-term investors ...